Salute e Benessere
BerGenBio Third Quarter Results 2024
Martin Olin , Chief Executive Officer of BerGenBio stated: "BerGenBio continues to progress its focused strategy to develop its lead AXL inhibitor bemcentinib in first-line NSCLC patients with mutations in the STK11 gene which, we believe, represent a significant commercial opportunity. The on-going BGBC016 study in this population continues to progress and recently announced Ph1b data supports the safety and adequate pharmacokinetics of bemcentinib in combination with current standard of care therapy. The Ph2a portion of the study continues to accrue patients both in the US and in Europe . We expect to share a first Interim Analysis in the first part of 2025."
The Q3 2024 Financial report is attached to this stock exchange announcement and the report and the Q3 2024 presentation are available at the Company's website https://www.bergenbio.com/investors/financial-reports .
BerGenBio's senior management team will provide a business update today at 10:00 am CET . The presentation will webcast live. To participate in the webcast, please use the following link:
https://channel.royalcast.com/landingpage/hegnarmedia/20241113_3/
A recording of the webcast will be available at www.bergenbio.com in the Investors/Financial Reports section ( https://www.bergenbio.com/investors/financial-reports ) shortly afterwards.
Martin Olin CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie , CFO, BerGenBio ASA
rune.skeie@bergenbio.com
Jan Lilleby
jl@lillebyfrisch.no
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, , a potentially first-in-class selective AXL inhibitor in clinical development for STK11 mutated NSCLC and preclinical development for severe respiratory infections.
BerGenBio is based in Bergen, Norway , with a subsidiary in Oxford, UK . The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/bergenbio-asa/r/bergenbio-third-quarter-results-2024,c4065505
The following files are available for download:
View original content: https://www.prnewswire.co.uk/news-releases/bergenbio-third-quarter-results-2024-302303714.html